Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 12, 2017, Pages

  Squizzato, Alessandro ^a   Bellesini, Marta ^a   Takeda, Andrea ^b   Middeldorp, Saskia ^c   Donadini, Marco Paolo ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ALL CAUSE MORTALITY; AMPUTATION; BLEEDING; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR DISEASE; COMPARATIVE EFFECTIVENESS; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; FOLLOW UP; HEART INFARCTION; HEART INFARCTION PREVENTION; HUMAN; ISCHEMIA; MONOTHERAPY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SAPHENOUS VEIN GRAFT; SYSTEMATIC REVIEW; THROMBOSIS; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; META ANALYSIS; MORTALITY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ASPIRIN; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TICLOPIDINE;

EID: 85038102498     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005158.pub4     Document Type: Review

References (122)

1. Slim AM, Fentanes E, Thomas DM, Slim JN, Triana T, Ahmadian HR, et al. ASpirin and Plavix Following Coronary Artery Bypass Grafting (ASAP-CABG): a randomized, double-blind, placebo-controlled pilot trial. British Journal of Medicine and Medical Research 2016; Vol. 14(3):1-10. 7245865
2. Kulik A, Le May MR, Voisine P, Tardif JC, Delarochelliere R, Naidoo S, et al. Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) trial. Circulation 2010;122:2680-7. 7245866
3. Une D, Al-Atassi T, Kulik A, Voisine P, Le May M, Ruel M. Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial. Circulation 2014;130 (suppl 1):S12-8. 7245867
4. Une D, Kulik A, Voisine P, Le May M, Ruel M. Correlates of saphenous vein graft hyperplasia and occlusion 1 year after coronary artery bypass grafting: analysis from the CASCADE randomized trial. Circulation 2013;128 (suppl 1):S213-8. 7245868
5. Belch JJ, Dormandy J, Biasi GM, Cairols M, Diehm C, Eikelboom B, et al. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. Journal of Vascular Surgery 2010;52:825-33. 3304081
6. Berger JS, Bhatt DL, Steg PG, Steinhubl SR, Montalescot G, Shao M, et al. Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. American Heart Journal 2011;162:98-105. 7245869
7. Berger PB, Bhatt DL, Fuster V, Steg PG, Fox KA, Shao M, et al. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation 2010;121:2575-83. 7245870
8. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. New England Journal of Medicine 2006;354:1706-17. 7245871
9. Hankey GJ, Johnston SC, Easton JD, Hacke W, Mas JL, Brennan D, et al. Effect of clopidogrel plus ASA vs. ASA early after TIA and ischaemic stroke: a substudy of the CHARISMA trial. International Journal of Stroke 2011;6:3-9. 7245872
10. Steinhubl SR, Bhatt DL, Brennen DM, Montalescot G, Hankey GJ, Eikelboom JW, et al. Aspirin prevent cardiovascular disease: the association aspirin dose and clopidogrel with thrombosis and bleeding. Annals of Internal Medicine 2009;150:379-86. 3304084
11. Mannacio VA, Di Tommaso L, Antignan A, De Amicis V, Vosa C. Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary arteRY bypaSS occlusion After off-pump procedures) randomised study. Heart 2012;98:1710-5. 3304086
12. Anand SS, Xie CC, Mehta S, Franzosi MG, Joyner C, Chrolavicius S, et al. Differences in the management and prognosis of women and men who suffer from acute coronary syndromes. Journal of the American College of Cardiology 2005;46:1845-51. 3304088
13. Budaj A, Yusuf S, Mehta SR, Fox KA, Tognoni G, Zhao F, et al. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation 2002;106(13):1622-6. 3304089
14. Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004;110(10):1202-8. 3304090
15. Lewis BS, Mehta SR, Fox KAA, Halon DA, Zhao F, Peters RJG, et al. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. American Heart Journal 2005;150:1177-84. 3304091
16. Mahoney EM, Mehta S, Yuan Y, Jackson J, Chen R, Gabriel S, et al. Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. American Heart Journal 2006;151:219-27. 3304092
17. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33. 3304093
18. Peters RJG, Mehta SR, Fox KAA, Zhao F, Lewis BS, Kopecky SL, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003;108(14):1682-7. 3304094
19. Yusuf S, Mehta SR, Zhao F, Gersh BJ, Commerford PJ, Blumenthal M, et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 2003;107(7):966-72. 3304095
20. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New England Journal of Medicine 2001;345:494-502. 3304096
21. Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk, Buchan AM. Fast assessment of stroke and transient ischemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurology 2007;6:961-9. 3304098
22. Gao G, Zheng Z, Pi Y, Lu B, Lu J, Hu S. Aspirin plus clopidogrel therapy increases early venous graft patency after coronary artery bypass surgery: a single-center, randomized, controlled trial. Journal of the American College of Cardiology 2010;56:1639-43. 3304100
23. Gasparovic H, Petricevic M, Kopjar T, Djuric Z, Svetina L, Biocina B. Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting. American Journal of Cardiology 2014;113:1660-7. 7245874
24. Strobl FF, Brechtel K, Schmehl J, Zeller T, Reiser MF, Claussen CD, et al. Twelve-month results of a randomized trial comparing mono with dual antiplatelet therapy in endovascularly treated patients with peripheral artery disease. Journal of Endovascular Therapy 2013;20:699-706. 7245875
25. Tepe G, Bantleon R, Brechtel K, Schmehl J, Zeller T, Claussen CD, et al. Management of peripheral arterial interventions with mono or dual antiplatelet therapy - the MIRROR study: a randomised and double-blinded clinical trial. European Journal of Radiology 2012;22:1998-2006. 3304102
26. Willerson JT, Cable G, Yeh ET, PROCLAIM Investigators. PROCLAIM: pilot study to examine the effects of clopidogrel on inflammatory markers in patients with metabolic syndrome receiving low-dose aspirin. Texas Heart Institute Journal 2009;36:530-9. 3304104
27. Benavente OR, Hart RG, McClure LA, Szychowski JM, Coffey CS, Pearce LA. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. New England Journal of Medicine 2012;367:817-25. 3304106
28. Rafiq S, Johansson PI, Kofoed KF, Lund JT, Olsen PS, Bentsen S, et al. Thrombelastographic hypercoagulability and antiplatelet therapy after coronary artery bypass surgery (TEG-CABG trial): a randomized controlled trial. Platelets 2017; Vol. 22:1-8. 7245877
29. Vavuranakis M, Latsios G, Aggelis D, Bosinakou I, Karambelas I, Tousoulis D, et al. Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels. Clinical Therapeutics 2006;28:860-71. 3304108
30. Zuo FT, Liu H, Wu HJ, Su N, Liu JQ, Dong AQ. The effectiveness and safety of dual antiplatelet therapy in ischemic cerebrovascular disease with intracranial and extracranial arteriostenosis in Chinese patients. Medicine 2017;96(1):e5497. 7245879
31. Akbulut M, Ozbay Z, Karaca I, Ilkay E, Gundogdu O, Arslan N. The effect of long-term clopidogrel use on neointimal formation after percutaneous coronary intervention. Coronary Artery Disease 2004;15:347-52. 3304110
32. NCT01559298. Aspirin versus aspirin + clopidogrel following transcatheter aortic valve implantation: the ARTE trial. clinicaltrials.gov/ct2/show/NCT01559298 Date first received: 21 March 2012. 3304166
33. Azar RR, Kassab R, Zoghbi A, Aboujaoudé S, El-Osta H, Ghorra P, et al. Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. American Heart Journal 2006;151:521.e1-e4. 3304112
34. Azcona L, Lopez Farre' AJ, Jimenez Mateos-Caceres P, Segura A, Rodriguez P, Modrego J, et al. Impact of clopidogrel and aspirin treatment on the expression of proteins in platelets from type-2 diabetic patients with stable coronary ischemia. Journal of Pharmaceutical Sciences 2012;101:2821-32. 3304114
35. Bernardi V, Szarfer J, Summay G, Mendiz O, Sarmiento R, Alemparte MR, et al. Long-term versus short-term clopidogrel therapy in patients undergoing coronary stenting (from the Randomized Argentine Clopidogrel Stent [RACS] Trial). American Journal of Cardiology 2007;99:349-52. 3304116
36. Dittrich R, Ritter MA, Kaps M, Siebler M, Lees K, Larrue V, et al. The use of embolic signal detection in multicenter trials to evaluate antiplatelet efficacy signal analysis and quality control mechanisms in the CARESS (clopidogrel and aspirin reduction emboli symptomatic carotid stenosis). Stroke 2006;37:1065-9. 3304118
37. Markus HS, Droste DW, Kaps M, Larrue V, Lees KR, Siebler M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection. The clopidogrel and aspirin for reduction of emboli in symptomatic carotid stenosis (CARESS) trial. Circulation 2005;111:2233-40. 3304119
38. Cassar K, Ford I, Greaves M, Bachoo P, Brittenden J. Randomized clinical trial of the antiplatelet effects of aspirin-clopidogrel combination versus aspirin alone after low limb angioplasty. British Journal of Surgery 2005;92:159-65. 3304121
39. Li Z, Wang Y, Zhao X, Liu L, Wang D, Wang C, et al. Treatment effect of clopidogrel plus aspirin within 12 hours of acute minor stroke or transient ischemic attack. JAMA 2016;5(3):e003038. 7245880
40. Liu L, Wong KS, Leng X, Pu Y, Wang Y, Jing J, et al. Dual antiplatelet therapy in stroke and ICAS. Subgroup analysis of CHANCE. Neurology 2015;85:1154-62. 7245881
41. Pan Y, Jing J, Chen W, Meng X, Li H, Zhao X, et al. Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: time course analysis of CHANCE. Neurology 2017;88(20):1906-11. 7245882
42. Wang X, Zhao X, Johnston SC, Xian Y, Hu B, Wang C, et al. Effect of clopidogrel with aspirin on functional outcome in TIA or minor stroke: CHANCE substudy. Neurology 2015;85:573-9. 7245883
43. Wang Y, Pan Y, Zhao X, Li H, Wang D, Johnston SC, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack (CHANCE) trial. One-year outcomes. Circulation 2015;132:40-6. 7245884
44. Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. New England Journal of Medicine 2013;368:11-9. 7245885
45. Wang Z, Xu C, Wang P, Wang Y, Xin H. Combined clopidogrel-aspirin treatment for high risk TIA or minor stroke does not increase cerebral microbleeds. Neurological Research 2015;37(11):993-7. 7245886
46. Deng QQ, Tang J, Chen C, Markus H, Huang YN, Zhao H, et al. The curative effect comparison of two kinds of therapeutic regimens on decreasing the relative intensity of microembolic signal in CLAIR trial. Journal of the Neurological Sciences 2016;367:18-21. 7245888
47. Lau AY, Zhao Y, Chen C, Leung TW, Fu J, Huang Y, et al. Dual antiplatelets reduce microembolic signals in patients with transient ischemic attack and minor stroke: subgroup analysis of CLAIR study. International Journal of Stroke 2014;Suppl A100:127-32. 7245889
48. Wang X, Lin WH, Zhao YD, Chen XY, Leung TW, Chen C, et al. The effectiveness of dual antiplatelet treatment in acute ischemic stroke patients with intracranial arterial stenosis: a subgroup analysis of CLAIR study. International Journal of Stroke 2013;8:663-8. 7245890
49. Wong KS, Chen C, Fu J, Chang HM, Suwanwela NC, Huang YN, et al. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. Lancet Neurology 2010;9(5):489-97. 7245891
50. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. New England Journal of Medicine 2005;352:1179-89. 3304125
51. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607-21. 3304127
52. Kelly RV, Hsu A, Topol E, Steinhubl S. The influence of body mass index on outcomes and the benefit of antiplatelet therapy following percutaneous coronary intervention. Journal of Invasive Cardiology 2006;18:115-9. 3304129
53. Mukherjee D, Topol EJ, Moliterno DJ, Brennan DM, Ziada K, Cho L, et al. Extracardiac vascular disease and effectiveness of sustained clopidogrel treatment. Heart 2006;92:49-51. 3304130
54. Saw J, Topol EJ, Steinhubl SR, Brennan D, Berger PB, Moliterno DJ, et al. Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat intervention. American Journal of Cardiology 2004;94:623. 3304131
55. Steinhubl SR, Berger PB, Mann JTIII, Fry ET, DeLago A, Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20. 3304132
56. Eriksson AC, Jonasson L, Lindahl TL, Hedbäck B, Whiss PA. Static platelet adhesion, flow cytometry and serum TXB2 levels for monitoring platelet inhibiting treatment with ASA and clopidogrel in coronary artery disease: a randomised cross-over study. Journal of Translational Medicine 2009;7:42. 3304134
57. Gwon HC, Hahn JY, Park KW, Song YB, Chae IH, Lim DS, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomised, multicenter study. Circulation 2012;125:505-13. 3304136
58. Geraghty OC, Kennedy J, Chandratheva A, Marquardt L, Buchan AM, Rothwell PM. Preliminary evidence of a high risk of bleeding on aspirin plus clopidogrel in aspirin-naïve patients in the acute phase after TIA or minor ischaemic stroke. Cerebrovascular Disorders 2010;29:460-7. 3304138
59. Hong KS, Lee SH, Kim EG, Cho KH, Chang DI, Rha JH, et al. Recurrent ischemic lesions after acute atherothrombotic stroke: clopidogrel plus aspirin versus aspirin alone. Stoke 2016;47(9):2323-30. 7245893
60. Hui Y. The clinical efficacy research for the treatment among intravenous unfractionated heparin, two antiplatelet agents (clopidogrel and aspirin) and single antiplatelet agent (aspirin) to acute cerebral infarction and transient ischemic attack (TIA). www.chictr.org.cn/showprojen.aspx?proj=11770 Date first registered: 16 February 2016. 7245895
61. Jagroop IA, Matsagas MI, Geroulakos G, Mikhailidis DP. The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease. Platelets 2004;15:117-25. 3304140
62. Kayacioglu I, Gunay R, Saskin H, Idiz M, Sensoz Y, Ates M, et al. The role of clopidogrel and acetylsalicylic acid in the prevention of early-phase graft occlusion due to reactive thrombocytosis after coronary artery bypass operation. Heart Surgery Forum 2008;11:E152-7. 3304142
63. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331-7. 3304144
64. Mujanovic E, Nurkic M, Caluk J, Terzic I, Kabil E, Bergsland J. The effect of combined clopidogrel and aspirin therapy after off-pump coronary surgery. A pilot study. Innovations 2009;4:265-8. 3304146
65. Storey RF, Bliden KP, Patil SB, Karunakaran A, Ecob R, Butler K, et al. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. Journal of the American College of Cardiology 2010;56:185-93. 3304148
66. Pal M, Prasad O, Fatima A, Bakki C, Ahmed M. Assessment of secondary recurrence of stroke in aspirin-clopidogrel combination therapy and aspirin monotherapy in transient ischemic attack patients in South India: a comparative study. Value in Health 2016;19(7):A863. 7245897
67. Pekdemir H, Cin VG, Camsari A, Cicek D, Akkus NM, Doven O, et al. A comparison of 1-month and 6-month clopidogrel therapy on clinical and angiographic outcome after stent implantation. Heart and Vessels 2003;18(3):123-9. 3304150
68. Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting. Circulation 2012;125:2015-26. 3304152
69. Park SJ, Park DW, Kim YH, Kang SJ, Lee SW, Lee CW, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. New England Journal of Medicine 2010;362:1374-82. 3304154
70. Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG, et al. A new strategy for discontinuation of dual antiplatelet therapy. Journal of the American College of Cardiology 2012;60:1340-8. 3304156
71. Steinhubl SR, Berger PB, Brennan DM, Topol EJ, for the CREDO Investigators. Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. Journal of the American College of Cardiology 2006;47:939-43. 3304158
72. Suh JW, Seung KB, Kwak CH, Kim KS, Hong SJ, Park TH, et al. Comparison of antiplatelet effect and tolerability of clopidogrel resinate with clopidogrel bisulfate in patients with coronary heart disease (CHD) or CHD-equivalent risks: a phase IV, prospective, double-dummy, parallel-group, 4-week non-inferiority trial. Clinical Therapeutics 2011;33:1057-68. 3304160
73. Thopte OS, Patil SP, Deshmukh RS. A study of aspirin plus clopidogrel versus aspirin alone on saphenous vein graft patency after coronary artery bypass graft surgery - an angiographic follow-up after three months. Indian Heart Journal 2014;66:S22. 7245899
74. Undas A, Stepień E, Branicka A, Wołkow P, Zmudka K, Tracz W. Thrombin formation and platelet activation at the site of vascular injury in patients with coronary artery disease treated with clopidogrel combined with aspirin. Kardiologia Polska (Polish Heart Journal) 2009;67(6):591-8. 7245901
75. Ussia GP, Scarabelli M, Mulè M, Barbanti M, Sarkar K, Cammalleri V, et al. Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation. American Journal of Cardiology 2011;108(12):1772-6. 7245903
76. Wang C, Yi X, Zhang B, Liao D, Lin J, Chi L. Clopidogrel plus aspirin prevents early neurologic deterioration and improves 6-Month outcome in patients with acute large artery atherosclerosis stroke. Clinical and Applied Thrombosis/hemostasis 2015;21(5):453-461. 7245905
77. Willoughby SR, Luu L, Cameron JD, Nelson AJ, Schultz CD, Worthley SG, et al. Clopidogrel improves microvascular endothelial function in subjects with stable coronary artery disease. Heart, Lung and Circulation 2014;23:534-41. 7245907
78. Wilson AM, Brittenden J, Bachoo P, Ford I, Nixon GF. Randomized controlled trial of aspirin and clopidogrel versus aspirin and placebo on markers of smooth muscle proliferation before and after peripheral angioplasty. Journal of Vascular Surgery 2009;50(4):861-9. 7245909
79. Xydakis D, Papadogiannakis A, Sfakianaki M, Vakouti E, Papachristoforou K. The combination of clopidogrel and acetylsalicylic acid inhibits more effective the platelet activation in haemodialysis patients with acute coronary syndromes and high C reactive protein. 41st Congress of the European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004. 3304162
80. Yi X, Lin J, Wang C, Zhang B, Chi W. A comparative study of dual versus mono-antiplatelet therapy in patients with acute large-artery atherosclerosis stroke. Journal of Stroke and Cerebrovascular Diseases 2014;23:1975-81. 7245911
81. Zhao L, Fletcher S, Weaver C, Leonardi-Bee J, May J, Fox S, et al. The effects of three anti-platelet drugs (aspirin, clopidogrel, dipyridamole) given singly or together on platelet and leucocyte function in healthy subjects and patients with previous ischemic stroke. Journal of Thrombosis & Haemostasis 2003;1(Suppl 1):P1010. 3304164
82. NCT00991029. Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design. clinicaltrials.gov/ct2/show/NCT00991029 Date first received: 7 October 2009. 7245913
83. Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet drugs. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141(2):e89S-119S.
84. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2017 update: a report from the American Heart Association. Circulation 2017;135:e146-603.
85. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-60.
86. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490-4.
87. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011;123:2736e2747.
88. Bedenis R, Stewart M, Cleanthis M, Robless P, Mikhailidis DP, Stansby G. Cilostazol for intermittent claudication. Cochrane Database of Systematic Reviews 2014, Issue 10. [DOI: 10.1002/14651858.CD003748.pub4]
89. Bedenis R, Lethaby A, Maxwell H, Acosta S, Prins MH. Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database of Systematic Reviews 2015, Issue 2. [DOI: 10.1002/14651858.CD000535.pub3]
90. Bowry AD, Brookhart MA, Choudhry NK. Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events. American Journal of Cardiology 2008;101:960-6.
91. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
92. Cosmi B, Rubboli A, Castelvetri C, Milandri M. Ticlopidine versus oral anticoagulation for coronary stenting. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: 10.1002/14651858.CD002133]
93. CURE Study Investigators. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme: rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. European Heart Journal 2000;21:2033-41.
94. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
95. Dorffler-Melly J, Buller HR, Koopman MM, Prins MH. Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database of Systematic Reviews 2003, Issue 3. [DOI: 10.1002/14651858.CD000535]
96. Dorffler-Melly J, Buller HR, Koopman MM, Prins MH. Antithrombotic agents for preventing thrombosis after infrainguinal arterial bypass surgery. Cochrane Database of Systematic Reviews 2003, Issue 2. [DOI: 10.1002/14651858.CD000536]
97. Dorffler-Melly J, Koopman MMW, Prins MH, Buller HR. Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database of Systematic Reviews 2005, Issue 1. [DOI: 10.1002/14651858.CD002071.pub2]
98. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
99. Wilkins E, Wilson L, Wickramasinghe K, Bhatnagar P, Leal J, Luengo-Fernandez R, et al. European Cardiovascular Disease Statistics 2017. Brussels (Belgium): European Heart Network, 2017.
100. Gaspoz JM, Coxson PG, Goldman PA, Williams LW, Kuntz KM, Hunink MGM, et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. New England Journal of Medicine 2002;346:1800-6.
101. Geraghty AJ, Welch K. Antithrombotic agents for preventing thrombosis after infrainguinal arterial bypass surgery. Cochrane Database of Systematic Reviews 2011, Issue 6. [DOI: 10.1002/14651858.CD000536.pub2]
102. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. New England Journal of Medicine 1993;329:673-82.
103. Hankey GJ, Sudlow CLM, Dunbabin DW. Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858.CD001246]
104. Higgins JPT, Deeks JJ. Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
105. Higgins JPT, Altman DG. Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
106. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
107. Main C, Palmer S, Griffin S, Jones L, Orton V, Sculpher M. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation. Health Technology Assessment 2004;40:1-56.
108. Morant SV, McMahon AD, Cleland JGF, Davey PG, MacDonald TM. Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicity. British Journal of Clinical Pharmacology 2003;57:188-98.
109. Main C, Palmer S, Griffin S, Jones L, Orton V, Sculpher M, et al. A rapid and systematic review on clinical effectiveness and cost-effectiveness of clopidogrel used in combination with aspirin compared to aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes (ACS) (assessment report). www.nice.org.uk/guidance/ta80/documents/acute-coronary-syndromes-clopidogrel-assessment-report2 (accessed prior to 28 November 2017).
110. Patrono C, Andreotti F, Arnesen H, Badimon L, Baigent C, Collet JP, et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. European Heart Journal 2011;32:2922-32.
111. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology 2009;62:1006-12.
112. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
113. Robertson L, Ghouri MA, Kovacs F. Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database of Systematic Reviews 2012, Issue 8. [DOI: 10.1002/14651858.CD002071.pub3]
114. Robless P, Mikhailidis D, Stansby G. Cilostazol for peripheral arterial disease. Cochrane Database of Systematic Reviews 2003, Issue 4. [DOI: 10.1002/14651858.CD001272]
115. Robless P, Mikhailidis D, Stansby GP. Antiplatelet agents for intermittent claudication. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD003748.pub2]
116. Sudlow CL, Mason G, Maurice JB, Wedderburn CJ, Hankey GJ. Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD001246.pub2]
117. Valentine N, van de Laar FA, van Driel ML. Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2012, Issue 11. [DOI: 10.1002/14651858.CD005449.pub2]
118. World Health Organization. Global Health Estimates 2015: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2015. World Health Reports. Geneva (Switzerland): World Health Organization, 2016.
119. Wong PF, Chong LY, Mikhailidis DP, Robless P, Stansby G. Antiplatelet agents for intermittent claudication. Cochrane Database of Systematic Reviews 2011, Issue 11. [DOI: 10.1002/14651858.CD001272.pub2]
120. Zakarija A, Bandarenko N, Pandey DK, Auerbach A, Raisch DW, Kim B, et al. Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. Stroke 2004;35:533-7.
121. Zhang Q, Wang C, Zheng M, Li Y, Li J, Zhang L, et al. Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis. Cerebrovascular Diseases (Basel, Switzerland) 2015;39:13-22.
122. Squizzato A, Keller T, Romualdi E, Middeldorp S. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. Cochrane Database of Systematic Reviews 2011, Issue 1. [DOI: 10.1002/14651858.CD005158.pub3]